UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of predictive markers of HIV disease progression in vaccine trials

Vaccine, 2009-03, Vol.27 (14), p.1997-2015

2009

Volltextzugriff (PDF)

Immunogenicity of a Recombinant Human Immunodeficiency Virus (HIV)–Canarypox Vaccine in HIV-Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study

The Journal of infectious diseases, 2003-03, Vol.187 (6), p.887-895

2003

Volltextzugriff (PDF)

HIV‐gp160 modulates differentially the production in vitro of IgG, IgA and cytokines by blood and tonsil B lymphocytes from HIV‐negative individuals

Clinical and experimental immunology, 2003-05, Vol.132 (2), p.304-308

2003

Volltextzugriff (PDF)

Polymorphisms in HLA Class I Genes Associated with both Favorable Prognosis of Human Immunodeficiency Virus (HIV) Type 1 Infection and Positive Cytotoxic T-Lymphocyte Responses to ALVAC-HIV Recombinant Canarypox Vaccines

Journal of Virology, 2001-09, Vol.75 (18), p.8681-8689

2001

Volltextzugriff (PDF)

Assessment of mucosal immunity to HIV-1

Expert review of vaccines, 2010-04, Vol.9 (4), p.381-394

2010

Volltextzugriff (PDF)

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

The New England journal of medicine, 2009-12, Vol.361 (23), p.2209-2220

2009

Volltextzugriff (PDF)

Secondary structure analysis of HIV-1-gp41 in solution and adsorbed to aluminum hydroxide by Fourier transform infrared spectroscopy

Biochimica et biophysica acta, 2007-03, Vol.1774 (3), p.351-358

2007

Volltextzugriff (PDF)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans

Retrovirology, 2012-09, Vol.9 (S2), p.P354-P354, Article P354

2012

Volltextzugriff (PDF)

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1

AIDS research and human retroviruses, 2000-12, Vol.16 (18), p.2019-2035

2000

Volltextzugriff (PDF)

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults

The Journal of infectious diseases, 2004-08, Vol.190 (4), p.702-706

2004

Volltextzugriff (PDF)

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

AIDS (London), 2008-07, Vol.22 (11), p.1313-1322

2008

Volltextzugriff (PDF)

A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)

The Journal of infectious diseases, 2006-12, Vol.194 (12), p.1672-1676

2006

Volltextzugriff (PDF)

Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients

AIDS (London), 2005-02, Vol.19 (3), p.279-286

2005

Volltextzugriff (PDF)

Safety and Immunogenicity of a Canarypox-Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher- and Lower-Risk Volunteers

The Journal of infectious diseases, 2001-05, Vol.183 (9), p.1343-1352

2001

Volltextzugriff (PDF)

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV

AIDS research and human retroviruses, 1998-10, Vol.14 Suppl 3, p.S291-S298

1998

Volltextzugriff (PDF)

Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)

Vaccine, 2005-07, Vol.23 (34), p.4292-4301

2005

Volltextzugriff (PDF)

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

Journal of Virology, 2002-03, Vol.76 (5), p.2206-2216

2002

Volltextzugriff (PDF)

Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing either HIV-1 Genes or the Gene for Rabies Virus G Protein

The Journal of infectious diseases, 2004-04, Vol.189 (7), p.1221-1231

2004

Volltextzugriff (PDF)

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

Vaccine, 2000-11, Vol.19 (7), p.684-693

2000

Volltextzugriff (PDF)

Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies

Journal of clinical immunology, 1991-05, Vol.11 (3), p.128-131

1991

Volltextzugriff (PDF)

Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines

Vaccine, 2004-06, Vol.22 (20), p.2626-2630

2004

Volltextzugriff (PDF)

Preparation of Clinical-Grade Recombinant Canarypox–Human Immunodeficiency Virus Vaccine–Loaded Human Dendritic Cells

The Journal of infectious diseases, 2002-11, Vol.186 (9), p.1242-1252

2002

Volltextzugriff (PDF)

Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults

Journal of acquired immune deficiency syndromes (1999), 2003-01, Vol.32 (1), p.9-17

2003

Volltextzugriff (PDF)

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection

AIDS research and human retroviruses, 1999-05, Vol.15 (7), p.633-645

1999

Volltextzugriff (PDF)

Future access to HIV vaccines: report from a WHO-UNAIDS consultation, Geneva, 2-3 October 2000

AIDS (London), 2001-05, Vol.15 (7), p.W27-W44

2001

Volltextzugriff (PDF)

1 – 25 von 392

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(320)
Mit Volltextzugriff
(318)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(249)
Life Sciences & Biomedicine
(203)
Humans
(141)
Female
(86)
Male
(82)
Biological And Medical Sciences
(78)
Medical Sciences
(65)
Adult
(56)
Middle Aged
(52)
Animals
(44)
Aged
(33)
Immunology
(32)
Infectious Diseases
(32)
Physical Sciences
(30)
Adolescent
(26)
Technology
(26)
Fundamental And Applied Biological Sciences. Psychology
(25)
Microbiology
(24)
Life Sciences
(23)
Risk Factors
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(11)
Revue Du Rhumatisme
(10)
Anesthesiology
(9)
The Journal Of Infectious Diseases
(9)
Plos One
(7)
Aids Research And Human Retroviruses
(6)
Aids
(5)
European Journal Of Biochemistry
(5)
Cheminform
(4)
Eye
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Use of predictive markers of HIV disease progression in vaccine trials

Immunogenicity of a Recombinant Human Immunodeficiency Virus (HIV)–Canarypox Vaccine in HIV-Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study

HIV‐gp160 modulates differentially the production in vitro of IgG, IgA and cytokines by blood and tonsil B lymphocytes from HIV‐negative individuals

Polymorphisms in HLA Class I Genes Associated with both Favorable Prognosis of Human Immunodeficiency Virus (HIV) Type 1 Infection and Positive Cytotoxic T-Lymphocyte Responses to ALVAC-HIV Recombinant Canarypox Vaccines

Assessment of mucosal immunity to HIV-1

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

Secondary structure analysis of HIV-1-gp41 in solution and adsorbed to aluminum hydroxide by Fourier transform infrared spectroscopy

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)

Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients

Safety and Immunogenicity of a Canarypox-Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher- and Lower-Risk Volunteers

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV

Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing either HIV-1 Genes or the Gene for Rabies Virus G Protein

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies

Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines

Preparation of Clinical-Grade Recombinant Canarypox–Human Immunodeficiency Virus Vaccine–Loaded Human Dendritic Cells

Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection

Future access to HIV vaccines: report from a WHO-UNAIDS consultation, Geneva, 2-3 October 2000

Suchergebnisse filtern